Drug Profile
VAX 128
Alternative Names: VAX128A; VAX128B; VAX128CLatest Information Update: 12 Sep 2017
Price :
$50
*
At a glance
- Originator VaxInnate
- Class Antivirals; Influenza A vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus H1N1 subtype
Most Recent Events
- 22 Mar 2016 No development reported - Phase-I for Influenza-A virus H1N1 subtype (Prevention) in USA (IM)
- 28 Dec 2012 VaxInnate's pandemic influenza vaccine candidate licensed to Emergent BioSolutions for marketing in USA
- 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China